Novel ATR/PARP1 Dual Inhibitors Demonstrate Synergistic Antitumor Efficacy in Triple‐Negative Breast Cancer Models

Abstract Concomitant inhibition of ataxia telangiectasia and Rad3‐related protein (ATR) and poly ADP‐ribose Polymerase (PARP) pathways is a promising strategy in cancer therapy, potentially expanding the clinical utility of ATR inhibitor (ATRi) and PARP inhibitor (PARPi). A novel series of ATR/PARP1...

Descrición completa

Detalles Bibliográficos

Principais autores:	Yuan Gao, Jiawei Zhou, Chen‐Chen Wang, Zong‐Hao Wang, Nian‐Dong Mao, Meng‐Lan He, Peng‐Peng Zhang, Ping Huang, Guo‐Wei Ye, Yu‐Qing Zhang, Feng‐Hui Tang, Hang Zhang, Tian Xie, Xiang‐Yang Ye
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2025-08-01
Series:	Advanced Science
Assuntos:	Anticancer ATR Dual Inhibitor PARP1 TNBC
Acceso en liña:	https://doi.org/10.1002/advs.202501916
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!